Related references
Note: Only part of the references are listed.Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma
Giovanni Rossi et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
Sarah A. Holstein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Jennifer Huang et al.
BONE MARROW TRANSPLANTATION (2018)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
O. Landgren et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
Dharshan Sivaraj et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Minimal residual disease testing after stem cell transplantation for multiple myeloma
A. M. Sherrod et al.
BONE MARROW TRANSPLANTATION (2016)
Better Therapy Requires Better Response Evaluation: Paving the Way for Minimal Residual Disease Testing for Every Myeloma Patient
Ola Landgren et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
Prolonged Survival With a Longer Duration of Maintenance Lenalidomide After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Idrees Mian et al.
CANCER (2016)
Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines
Kenneth C. Anderson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Maintenance Therapy after Autologous Haematopoietic Stem Cell Transplantation (auto-HSCT) in Multiple Myeloma Patients with and without Minimal Residual Disease (MRD)
Maxim V. Solovev et al.
BLOOD (2016)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Sham Mailankody et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Minimal Residual Disease: What Are the Minimum Requirements?
Mark Roschewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Murielle Roussel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders et al.
BLOOD (2013)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Minimal Residual Disease in Myeloma: Are We There Yet?
Andrew J. Hart et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow
Xiaohui Zhao et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
